Home > Healthcare > Pharmaceuticals > Finished Drug Form > Branded Generics Market

Branded Generics Market Trends

Report ID: GMI6565
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Branded Generics Market Trends

The increasing prevalence of chronic diseases is expected to boost the market expansion. For instance, according to the Centers for Disease Control and Prevention (CDC) report, heart disease is the leading cause of death for men, and women in the U.S. In 2021, about 695,000 people in the U.S. died from heart disease. About 1 in 20 adults aged 20 and older have coronary artery disease. As chronic conditions become more widespread globally, the demand for long-term, affordable medications grows exponentially, thereby supplementing the market demand. Furthermore, chronic diseases often require consistent medication regimens to control symptoms and prevent exacerbations. Therefore, branded generics offer a viable solution, ensuring that patients can adhere to their prescribed therapies without compromise, thereby fostering the market share.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The branded generics industry was worth USD 238.4 billion in 2022 and is estimated to grow at 6.1% CAGR from 2023-2032, driven by the rising number of patent expiry boosting the demand for branded generics.

The anti-hypertensive segment held a 16.7% share of the market in 2022 and is set to witness significant growth through 2032 attributed to the increasing prevalence of hypertension.

The North America branded generics market accounted for a 40.8% market share in 2022 and is poised to expand rapidly through 2032 due to the presence of a robust healthcare infrastructure and the rising emphasis on cost-effective treatments.

Demand for calcium aluminosilicate recorded USD 0.7 billion in 2022 and may expand at a significant pace from 2023-2032 due to rising concerns over water scarcity along with the need to ensure safe and clean drinking water